MRTX - Mirati Therapeutics, Inc.
| Previous Close | 58.85 |
| Open | 59.00 |
| Bid | 55.05 x 1100 |
| Ask | 60.30 x 2200 |
| Day's Range | 57.50 - 61.20 |
| 52 Week Range | 4.75 - 65.35 |
| Volume | 358,154 |
| Avg. Volume | 552,329 |
| Market Cap | 1.94B |
| Beta | 2.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.78 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.38 |
- PR Newswire•yesterday
Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
SAN DIEGO, Aug. 16, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology company, today announced that a KRAS G12C poster will be presented by scientists from Mirati and Array BioPharma at the 255th American Chemical Society (ACS) National Meeting & Exposition being held in Boston, MA, August 19-23, 2018. "We are looking forward to the first public presentation of our orally-active series of covalent inhibitors of KRAS G12C.
- Associated Press•16 days ago
Mirati: 2Q Earnings Snapshot
The San Diego-based company said it had a loss of 94 cents per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
- PR Newswire•16 days ago
Mirati Therapeutics Reports Second Quarter Financial Results
SAN DIEGO , Aug. 1, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2018 ...
- Zacks•17 days ago
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
Style Box ETF report for DWAS
Motley Fool•21 days agoHow to Invest in Clinical-Stage Biotechs Without Losing Money
Clinical-stage biotechs can wreak havoc on your portfolio. Here's one approach that can limit the potential damage while still allowing you to take a long-term approach to capital appreciation.
- PR Newswire•24 days ago
Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress
SAN DIEGO , July 24, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that two abstracts highlighting data from ongoing clinical ...
- ACCESSWIRE•last month
Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks
Stock Research Monitor: KTOV, LOXO, and MDGL LONDON, UK / ACCESSWIRE / July 17, 2018/ If you want a free Stock Review on MRTX sign up now at www.wallstequities.com/registration . Today, WallStEquities.com ...
- PR Newswire•2 months ago
Mirati Therapeutics Added to Russell 2000® Index
SAN DIEGO, June 25, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, today announced that it has been added to the Russell 2000® Index, effective as of the open of the market on Monday, June 25, 2018, following Russell's annual reconstitution of its comprehensive set of U.S. and global equity indexes. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market. The index is a subset of the Russell 3000® Index and represents approximately 10 percent of the total market capitalization of that index.
- Zacks•2 months ago
Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?
Style Box ETF report for DWAS
- PR Newswire•2 months ago
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , June 11, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 3,162,500 shares of its common ...
- Motley Fool•2 months ago
Here's Why Mirati Therapeutics, Inc. Is Rising Today
Wall Street cheers after the company announced favorable terms from a just-announced capital raise. Here's what investors need to know.
- PR Newswire•2 months ago
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO, June 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the pricing of an underwritten public offering of 2,750,000 shares of its common stock at a price to the public of $38.85 per share. In addition, and in lieu of common stock, Mirati is offering to certain investors pre-funded warrants to purchase up to an aggregate of 421,650 shares of common stock at a purchase price of $38.849 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $123.2 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.
- PR Newswire•2 months ago
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 6, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares are being offered by Mirati.
- PR Newswire•3 months ago
Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting
SAN DIEGO , May 31, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that new data from the ongoing Phase 1b clinical trial of single ...
- PR Newswire•3 months ago
Mirati Therapeutics To Present At Jefferies 2018 Global Healthcare Conference
SAN DIEGO , May 30, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the Jefferies Annual Global Healthcare Conference in New York ...
- Zacks•3 months ago
Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session
Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.
- Associated Press•3 months ago
Mirati: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 51 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- PR Newswire•3 months ago
Mirati Therapeutics Reports First Quarter Financial Results
SAN DIEGO , May 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company, today reported financial results for the first quarter ended March 31, 2018 . "We ...
Motley Fool•4 months agoCan These Top-Performing Biotech Stocks Keep Climbing?
Over the past year, these two biotech stocks outperformed nearly all their peers. Can they keep it going?
- PR Newswire•4 months ago
Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
SAN DIEGO, April 24, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) (the Company or Mirati), a clinical-stage targeted oncology company, today provided a progress update on its lead development programs and announced updated, positive clinical trial data for sitravatinib, a spectrum selective kinase inhibitor, and mocetinostat, a class I and IV HDAC inhibitor. The Company has been evaluating sitravatinib and mocetinostat in separate Phase 2 clinical trials in combination with checkpoint inhibitor therapy in non-small cell lung cancer (NSCLC) patients whose disease had progressed following prior treatment with a checkpoint inhibitor.
- Simply Wall St.•5 months ago
Did Mirati Therapeutics Inc’s (NASDAQ:MRTX) Recent Earnings Growth Beat The Trend?
Examining Mirati Therapeutics Inc’s (NASDAQ:MRTX) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, whichRead More...
- PR Newswire•5 months ago
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results
SAN DIEGO , March 8, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, today reported financial results for the fourth quarter and full-year ...
- PR Newswire•5 months ago
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
SAN DIEGO , March 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at three upcoming healthcare conferences. Cowen 38 th Annual ...
